Merck Releases 12-Week Flea, Tick Medicine

Bravecto (fluralaner) tablets for dogs kill fleas and multiple tick species for 12 weeks in a single dose.

Bravecto is effective against fleas and four types of ticks.

Merck Animal Health today upped the ante in the world of flea and tick preventives with a flavored chew proven to be effective for 12 weeks at a time.

"Bravecto is a breakthrough innovation that offers pet owners and veterinarians something that no other product does—the longest-lasting oral flea and tick prevention currently available," said KJ Varma, senior vice president of research and development at Summit, N.J.-based Merck.

The product is indicated to kill fleas for 12 weeks, the black-legged tick, American dog tick and brown dog tick for 12 weeks, and the Lone Star tick for eight weeks. The 12-week claims do not apply to dogs less than 6 months old.

The active ingredient, fluralaner, is a new ectoparasiticide belonging to the isoxazoline group, Merck noted.

The chew may be given to help control flea allergy dermatitis, the manufacturer added.

Bravecto's five dosages are based on a dog's weight: 4.4 to 9.9 pounds, 9.9 to 22 pounds, 22 to 44 pounds, 44 to 88 pounds and 88 to 123 pounds.

Clinical trials revealed the most common adverse reactions to be vomiting, decreased appetite, diarrhea, lethargy, polydipsia and flatulence.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.